{"version":"1.0","type":"link","title":"Lorlatinib in patients with -positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.","author_name":"Bearz A 외","author_url":"https://prs-insight.online/author/Bearz%20A","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/94584","thumbnail_width":1200,"thumbnail_height":630}